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OBJECTIVES: The purpose of this analysis was to explore—from a theoretical welfare 
economics perspective—how whether drugs are substitutes or complements affects the 
design of optimal coinsurance. METHODS: A theoretical economics model of a 
duopoly market for two medicines was constructed. In the model, there are consumers 
who ﬁrst purchase insurance and then consume drugs if they become sick. Drug 
producers set the price of the drugs in the model. The results from the model are then 
used to inform how beneﬁts should be designed differently whether drugs are comple-
ments or substitutes. Speciﬁc real-world examples are interpreted in light of these 
predictions, and special attention is given to the implications for value-based insurance 
design. RESULTS: The results from the model show that drugs that are complements 
should have a lower coinsurance than drugs that are substitutes. The model also sug-
gests that when drugs are substitutes, consumers choose levels of coinsurance that are 
too low (i.e. consumer is insured too much). This may or may not be the case for 
complements. From society’s perspective (including drug makers’ proﬁts), consumers 
choose levels of coinsurance that are too high (consumer is insured too little) when 
drugs are complements. This may or may not be the case for substitutes. CONCLU-
SIONS: The results from the model can be used to inform the design of pharmaceutical 
beneﬁts to make the consumer as well off as possible. When drugs are complements, 
a lower burden of payment should be implemented for the consumer. Examples of 
this would be HIV/AIDS drugs, malaria drugs or bone loss prevention (Calcium/
Vitamin D). When drugs are substitutes, a higher burden of payment should be 
implemented. Examples would include statins, for example, when one treatment is 
chosen from many options. Value-based insurance design needs to consider this 
complementarity in addition to the potential for under-use.
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OBJECTIVES: Economic evidence in terms of different types of pharmacoeconomic 
data serves a crucial role in informing decisions on selecting pharmaceuticals, both 
for national drug lists and insurance reimbursement lists. Iranian Drug Selection Com-
mittee as the responsible body for granting marketing authorization for pharmaceu-
ticals has made some efforts, however fragmented, to consider economic evidence in 
its decisions. This paper aimed at evaluating the role of economic evidence in the 
Iranian Food and Drug Organization’s current marketing authorization policy. 
METHODS: At ﬁrst, we captured the past and current situation of utilizing pharma-
coeconomic data for granting pharmaceutical marketing authorization by conducting 
a number of exploratory interviews and reviewing relevant ofﬁcial documents on rules 
and regulations. Thereafter, within an analytic framework, we evaluated the cost-
effectiveness proﬁle of pharmaceuticals which were granted marketing authorization 
within the period of obligatory economic evidence submission. RESULTS: Pharmaco-
economic evaluations and their potential role in assuring value for money was ﬁrst 
introduced to Iranian pharmaceutical policy-makers in 2003 by World Health Orga-
nization. Only after 5 years did The Iranian Drug Selecting Committee begin to launch 
The Pharmacoeconomic Subcommittee in addition to developing certain forms for 
collecting pharmacoeconomic data and making pharmaceutical companies ﬁll these 
forms out within their routine submission process for requesting marketing authoriza-
tion. However, this regulation last only 6 months and was abolished in July 2008. 
Currently there is no room for submitting economic data in pharmaceutical dossiers. 
CONCLUSIONS: Iran pharmaceutical regulatory authority suffers from lack of a 
clearly deﬁned policy on taking the advantage of the results of pharmacoeconomic 
evaluations either in granting marketing authorization or drug reimbursement deci-
sions. Thus, the need for a clear policy in this regard is unequivocal.
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OBJECTIVES: In Brazil a hybrid health care system that comprises a public and a 
private systems is in place. The objective of this exploratory analysis is to better 
understand the distribution of resources in terms of annual health care expenditures 
per capita in Brazil in both systems. METHODS: A review of public databases was 
conducted to raise data on both ﬁnancial expenditures and the population assigned 
in each system. Sources were: Instituto Brasileiro de Geograﬁa e Estatística—IBGE 
(Brazilian Institute for Statistics), Ministério da Saúde (Brazilian Ministry of Health), 
Agência Nacional de Saúde Suplementar—ANS (Brazilian agency which regulates the 
private health care sector) and available studies in Portuguese. RESULTS: The total 
annual health care expenditure (added value) in Brazil is R$ 137.9 billion and it 
represented 8.4% over the GDP in 2007 (IBGE, 2009). Eighty billion Reais were spent 
by the private health care system (58.3%), whereas R$ 57.5 billion (41.7%) derived 
from the public sector. On the public side, 50.6% of the expenditures are from the 
federal government, 24.5% from the states governments and the remaining 24.9% 
are funded by the municipalities (Ugá, 2005). Also, 192 million people live in Brazil, 
79% of the population depends on the public health care system and 21% rely on the 
private health care system (IBGE, 2009 and ANS, 2009). As a result, a signiﬁcant 
difference can be observed in the annual health care expenditure per capita in the 
private sector when compared to the one found in the public sector, R$ 2,015 vs. R$ 
383, respectively (US$ 1 = R$ 1,711 Dec 10, 2009). CONCLUSIONS: The annual 
health care expenditure per capita in Brazil in the private sector is 5.3 fold the one 
found in the public sector. Further research is recommended to comprehend whether 
such a difference might impact on the clinical outcomes of each system.
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OBJECTIVES: In 2007, about 70% of the nearly 40 million hospital stays involved 
some type of procedure, and about 30% of all stays involved an operating room 
procedure. Some of these procedures have been associated with much more rapidly 
increasing hospital costs than others. Using a nationally representative sample, we 
examined the inpatient hospital stays for procedures with the most rapidly increasing 
hospital costs during this time period. METHODS: This study presents data from the 
Healthcare Cost and Utilization Project Nationwide Inpatient Sample and identiﬁes 
ten procedures generating the most rapidly increasing hospital costs between 2004 
and 2007. Speciﬁcally, it compares estimates of the portion of the cost increase result-
ing from greater use of procedures versus a rise in the mean cost per stay. RESULTS: 
Aggregate costs for stays in which a procedure was performed grew by 7.2% between 
2004 and 2007, totaling $296 billion in 2007. About two-thirds of this growth in 
aggregate costs was due to an increase in the number of hospitalizations (4.4%), and 
one-third was due to a rise in the mean cost per stay (2.6%). Growth in volume drove 
the growth of aggregate costs among stays for bone marrow transplant and open 
prostatectomy—procedures with the most rapidly increasing hospital costs during this 
period—as well as stays for incision and drainage of skin, knee arthroplasty, lobec-
tomy or pneumonectomy, and aortic resection. In contrast, growth in mean cost per 
stay—that is, greater intensity of the use of services—contributed notably to the 
aggregate cost increases for mastectomy, cancer chemotherapy, nephrotomy and neph-
rostomy, and spinal fusion. CONCLUSIONS: Identifying the procedures that generate 
the most rapid increases in hospital costs and evaluating the drivers of these increases 
may contribute to a more informed discussion of overall health care cost increases.
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OBJECTIVES: The aim of our study is to analyze the annual health insurance reim-
bursement cost of spa services and its distribution according to the type of services in 
Hungary. METHODS: The data is derived from Hungarian National Health Insur-
ance Fund Administration (OEP), the only health care ﬁnancing agency in Hungary. 
We analyzed the annual treatment of 2007 and its health insurance cost. We identiﬁed 
the following spa services with health insurance reimbursement in Hungary: spa pool 
of medical water, tub-bath of medical water, mud pack, medicinal weight-bath, 
effervescent-bath, medical health massage, sub-aquean spray massage, sub-aquean 
health care gymnastics for groups, complex balneotherapeutical service, health swim 
therapy for groups under 18. We calculate the annual health insurance reimbursement 
of different kind of spa services and its distribution. RESULTS: 8,16 million treat-
ments of medical spa were done in Hungary at 2007 and OEP spent 4,434 billion 
HUF (Hungarian Forint) for reimbursement of these interventions. This sum of money 
is equal to 0,617 % of medicinal-prevention cost (718,717 billion HUF). The annual 
health insurance reimbursement of the single spa services and its distributions was the 
follows: spa pool of medical water (1144 million HUF, 25,81%), tub-bath of medical 
water (5,4 million HUF, 0,12%), mud pack (369,6 million HUF, 8,34%), medicinal 
weight-bath (96,4 million HUF, 2,17%), effervescent-bath (58,1 million HUF, 
1,31%), medical health massage (1291 million HUF, 29,11%), sub-aquean spray 
massage (471,3 million HUF, 10,63%), sub-aquean health care gymnastics for groups 
(321,9 million HUF, 7,26%), complex balneotherapeutical service (404,9 million 
HUF, 9,13%), health swim therapy for groups under 18 (271,6 million HUF, 6,13%). 
CONCLUSIONS: The cost of spa services is 0,617 % of medicinal-prevention cost in 
Hungary. The greatest items are medical health massage and spa pool of medical 
water.
